![HCA Capital: Wrap up from 2024 Life Science seminar](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
Log in to your Inderes Free account to see all free content on this page.
Pharma Equity Group
0.296 DKK +9.63%HC Andersen Capital receives payment from Pharma Equity Group for a DigitalIR/Corporate Visibility agreement. See disclaimer.
12 investors are following this company
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
PEG
Daily low / high price
0.259 / 0.299
DKK
Market cap
302.8M DKK
Turnover
691.44K DKK
Volume
2.5M
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
![Claus Thestrup Claus Thestrup](https://www.inderes.se/cdn-cgi/image/format=auto,width=128,height=128,quality=90,fit=cover/https://content.inderes.se/assets/637ef734-dcbf-426c-bf91-0ac4a79aa71e.png)
Claus Thestrup
CEO, Sweden
Latest videos
Financial calendar
Interim report
16.08.2024
Interim report
15.11.2024
ShowingAll content types
![HCA Capital: Wrap up from 2024 Life Science seminar](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
![Life Science seminar 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ab49c0b1-56d0-4e1c-b729-6c79c89b7be2.png)
Life Science seminar 2024
Results of extraordinary general meeting in Pharma Equity Group A/S
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
![Pharma Equity Group: Investors appreciate eventful, and mostly positive, 1. quarter 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/e63e4a03-8498-4f91-be79-24be09bcc666.png)
Pharma Equity Group: Investors appreciate eventful, and mostly positive, 1. quarter 2024
The Board of Director's decision to issue convertible loans
Consolidated interim report 1 January – 31 March 2024
Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S
Notice convening the extraordinary general meeting of Pharma Equity Group A/S
![Pharma Equity Group (One-pager): Continues to move forward but the shares continues to slide](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/e63e4a03-8498-4f91-be79-24be09bcc666.png)
Pharma Equity Group (One-pager): Continues to move forward but the shares continues to slide
Major shareholder announcement - Pharma Equity Group A/S
Passing of the General Meeting of Pharma Equity Group A/S
The Board of Director's decision to issue convertible loans
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.
Notice convening the annual general meeting in Pharma Equity Group A/S
Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009
Completion of subscription of convertible loans
Correction: Pharma Equity Group A/S - Annual Report 2023
Pharma Equity Group A/S - Annual Report 2023
![HCA Biosnack update: Biotech and Life Science stocks outperform as the general stock market moves to record highs.](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=contain/https://content.inderes.se/assets/06aef4ac-f94b-407d-ac4d-dffe67b0f7a5.png)